E. Eric Tokat

E. Eric Tokat is a partner and a founding member of the Healthcare practice at Centerview Partners. During his career, Mr. Tokat advised numerous clients on a broad range of strategic advisory assignments and transactions exceeding $350 billion in value across developed and emerging markets.

Mr. Tokat’s other healthcare transactions include: Pfizer’s $68bn acquisition of Wyeth; $33bn LBO of HCA; AstraZeneca's $15bn acquisition of MedImmune; Celgene’s $3bn acquisition of Pharmion; New River Pharmaceuticals’ $3bn sale to Shire; ICOS' $2bn sale to Eli Lilly; LifeCell's $2bn sale to Kinetic Concepts; Cougar Biotechnology's $1bn sale to J&J; Haemonetics' acquisition of Pall Corp.'s Blood Filtration Business; Thirdwave Technologies' sale to Hologic; Virochem’s sale to Vertex; the LBO of Symbion; Intercell’s acquisition of Iomai; American Bioscience’s merger with American Pharmaceutical Partners.

Mr. Tokat serves on a number of not-for-profit boards, including: a trustee at the Brookings Institution, chair of the Audit Committee at the IRC (International Rescue Committee), and vice chair of the Board of the Columbia University's Mailman School of Public Health. He is a member of the Council on Foreign Relations.

Mr. Tokat received his BA from Bogazici University and MIA from Columbia University.